Literature DB >> 1726691

Isoelectric focusing and immunoblotting analysis of thyroglobulin from different thyroid diseases.

A Olivieri1, A Marzullo, G B Salabé, E Gilardi, C Fazzini, S Carta.   

Abstract

Thyroglobulins (Tgs) have been obtained from macro-microfollicular goiter, toxic adenomas, papillary carcinomas and metastatic lympho-node and chromatographed by gel filtration. The 19S Tgs so obtained have been characterized by isoelectric focusing (IEF) and immunoblotting. IEF showed microheterogeneity pattern of Tgs from normal tissue, macro-microfollicular goiter and toxic adenomas to be within pH range from 4.2 to 4.5, while that from papillary carcinomas and metastatic lympho-node showed a wider microheterogeneity. Passive blotting of focused Tgs and immunoreaction with rabbit anti-Tg peroxidase conjugated antibody have been carried out and a positive reaction for all examined samples have been evidenced. Also two bands, focused at more cathodic pH value (pH 4.7), observed in IEF patterns of Tgs from carcinomas and metastatic lympho-node, gave a positive reaction with anti-Tg conjugated antibody. These differences observed in IEF and immunoblotting patterns of Tgs from papillary carcinomas and metastatic lympho-node are discussed in this report.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726691

Source DB:  PubMed          Journal:  Thyroidology        ISSN: 1121-7596


  2 in total

1.  Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer.

Authors:  D Grammatopoulos; Y Elliott; S C Smith; I Brown; R J Grieve; E W Hillhouse; M A Levine; M D Ringel
Journal:  Mol Pathol       Date:  2003-06

2.  Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation.

Authors:  D Thomas; V Liakos; E Vassiliou; F Hatzimarkou; A Tsatsoulis; P Kaldrimides
Journal:  J Endocrinol Invest       Date:  2007-03       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.